ЛИТЕРАТУРА
1. Эндокринология : национальное руководство / под ред. И.И. Дедова, Г.А. Мельниченко. М. : ГЭОТАР-Медиа, 2009.
2. Conn J.W. PresidentiaL address. I. Painting background. II. Primary aLdosteronism, a new cLinicaL syndrome // J. Lab. CLin. Med. 1955. VoL. 45. P. 3-17.
3. Conn J.W., Cohen E.L., Rovner D.R., Nesbit R.M. Normokalemic primary aldosteronism. A detectable cause of curable "essential" hypertension // JAMA. 1965. Vol. 193. P. 200-206.
4. Conn J.W. The evolution of primary aldosteronism 1954-1967 //Harvey Lect. 1966-1967. Vol. 62. P. 257-291.
5. Kaplan N.M. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism // Ann. Intern. Med. 1967. Vol. 66. P. 1079-1090.
6. Fishman L.M., Kuchel O., Liddle G.W. et al. Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria // JAMA. 1968. Vol. 205. P. 497-502.
7. Berglund G., Andersson O., Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample // Br. Med. J. 1976. Vol. 2. P. 554-556.
8. Tucker R.M., Labarthe D.R. Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 through 1975 // Mayo Clin. Proc. 1977. Vol. 52. P. 549-545.
9. Streeten D.H., Tomycz N., Anderson G.H. Reliability of screening methods for the diagnosis of primary aldosteronism // Am. J. Med. 1979. Vol. 67. P. 403-413.
10. Sinclair A.M., Isles C.G., Brown I. et al. Secondary hypertension in a blood pressure clinic // Arch. Intern. Med. 1987. Vol. 147. P. 1289-1293.
11. Andersen G.S., Toftdahl D.B., Lund J.O. et al. The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981 // J. Hum. Hypertens. 1988. Vol. 2. P. 187-189.
12. Grim C.E., Weinberger M.H., Higgins J.T., Kramer N.J. Diagnosis of secondary forms of hypertension. A comprehensive protocol // JAMA. 1977. Vol. 237. P. 1331-1335.
13. Gordon R.D., Stowasser M., Tunny T.J. et al. High incidence of primary aldosteronism in 199 patients referred with hypertension // Clin. Exp. Pharmacol. Physiol. 1994. Vol. 21. P. 315-318.
14. Fardella C.E., Mosso L., Gomez-Sanchez C. et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology // J. Clin. Endocrinol. Metab. 2000. Vol. 85. P. 1863-1867.
15. Lim P.O., Dow E., Brennan G. et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population // J. Hum. Hypertens. 2000. Vol. 14. P. 311-315.
16. Loh K.C., Koay E.S., Khaw M.C. et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore // J. Clin. Endocrinol. Metab. 2000. Vol. 85. P. 2854-2859.
17. Mulatero P., Stowasser M., Loh K.C. et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents // J. Clin. Endocrinol. Metab. 2004. Vol. 89. P. 1045-1050.
18. Mosso L., Carvajal C., Gonzalez A. et al. Primary aldosteronism and hypertensive disease // Hypertension. 2003. Vol. 42. P. 161-165.
19. Schwartz G.L., Turner S.T. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity // Clin. Chem. 2005. Vol. 51. P. 386-394.
20. Hannemann A., Bidlingmaier M., Friedrich N. et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies // Eur. J. Endocrinol. 2012. Vol. 167. P. 7-15.
21. Milliez P., Girerd X., Plouin P.F., Blacher J. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism // J. Am. Coll. Cardiol. 2005. Vol. 45. P. 1243-1248.
22. Stowasser M., Sharman J., Leano R., Gordon R.D. et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I // J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 5070-5076.
23. Funder J.F., Carey R.M., Mantero F., Murad M.H. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline // J. Clin. Endocrinol. Metab. 2016. Vol. 101, N 5. P. 1889-1916.
24. Stowasser M., Gordon R.D., Gunasekera T.G., Cowley D.C. et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after "non-selective" screening of hypertensive patients // J. Hypertens. 2003. Vol. 21. P. 2149-2157.
25. Wu V.C., Kuo C.C., Wang S.M., Liu K.L. et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment // J. Hypertens. 2011. Vol. 29. P. 1778-1786.
26. Hiramatsu K., Yamada T., Yukimura Y., Komiya I. et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients // Arch. Intern. Med. 1981. Vol. 141. P. 1589-1593.
27. Stowasser M., Ahmed A.H., Pimenta E., Taylor P.J. et al. Factors affecting the aldosterone/renin ratio // Horm. Metab. Res. 2012. Vol. 44. P. 170-176.
28. Young W.F., Stanson A.W., Thompson G.B., Grant C.S. et al. Role for adrenal venous sampling in primary aldosteronism // Surgery. 2004. Vol. 136. P. 1227-1235.
29. Nwariaku F.E., Miller B.S., Auchus R., Holt S. et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome // Arch. Surg. 2006. Vol. 141. P. 497-502; discussion P. 502-493.
30. Young W.F. Primary aldosteronism: renaissance of a syndrome //Clin. Endocrinol. 2007. Vol. 66. P. 607-618.
31. Young W.F. Jr. Conventional imaging in adrenocortical carcinoma: update and perspectives // Horm. Cancer. 2011. Vol. 2. P. 341-347.
32. Dluhy R.G., Anderson B., Harlin B., Ingelfinger J. et al. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood // J. Pediatr. 2001. Vol. 138. P. 715-720.
33. So A., Duffy D.L., Gordon R.D., Jeske Y.W. et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity // J. Hypertens. 2005. Vol. 23. P. 1477-1484.
34. Geller D.S., Zhang J., Wisgerhof M.V., Shackleton C. et al. A novel form of human mendelian hypertension featuring nonglucocorticoidremediable aldosteronism // J. Clin. Endocrinol. Metab. 2008. Vol. 93. P. 3117-3123.
35. Young W.F., Stanson A.W., Thompson G.B., Grant C.S. et al. Role for adrenal venous sampling in primary aldosteronism // Surgery. 2004. Vol. 136. P. 1227-1235.
36. Wolley M.J., Gordon R.D., Ahmed A.H., Stowasser M. Does contra-lateral suppression at adrenal venous sampling predict outcome following unilateral adrenalectomy for primary aldosteronism? A retrospective study // J. Clin. Endocrinol. Metab. 2015. Vol. 100. P. 1477-1484.
37. Young W.F., Stanson A.W. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? // Clin. Endocrinol. 2009. Vol. 70. P. 14-17.
38. Gordon R.D. Primary aldosteronism // J. Endocrinol. Invest. 1995. Vol. 18. P. 495-511.
39. Ganguly A., Dowdy A.J., Luetscher J.A., Melada G.A. Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma // J. Clin. Endocrinol. Metab. 1973. Vol. 36. P. 401-404.
40. Gordon R.D., Gomez-Sanchez C.E., HamLet S.M., Tunny T.J. et aL. Angiotensin-responsive aLdosterone-producing adenoma masquerades as idiopathic hyperaLdosteronism (IHA: adrenaL hyperpLasia) or Low-renin essentiaL hypertension // J. Hypertens. SuppL. 1987. VoL. 5. P. S103-S106.
41. Bystrom C.E., SaLameh W., Reitz R., CLarke N.J. PLasma renin activity by LC-MS/MS: deveLopment of a prototypicaL cLinicaL assay reveaLs a subpopuLation of human pLasma sampLes with substantiaL peptidase activity // CLin. Chem. 2010. VoL. 56. P. 1561-1569.
42. Espiner E.A., Ross D.G., YandLe T.G., Richards A.M. et aL. Predicting surgicaLLy remediaL primary aLdosteronism: roLe of adrenaL scanning, posture testing, and adrenaL vein sampLing // J. CLin. EndocrinoL. Metab. 2003. VoL. 88. P. 3637-3644.
43. PhiLLips J.L., WaLther M.M., PezzuLLo J.C., Rayford W. et aL. Predictive vaLue of preoperative tests in discriminating biLateraL adrenaL hyperpLasia from an aLdosterone-producing adrenaL adenoma // J. CLin. EndocrinoL. Metab. 2000. VoL. 85. P. 4526-4533.
44. Sywak M., Pasieka J.L. Long-term foLLow-up and cost benefit of adrenaLectomy in patients with primary hyperaLdosteronism // Br. J. Surg. 2002. VoL. 89. P. 1587-1593.
45. ReimeL B., Zanocco K., Russo M.J., Zarnegar R. et aL. The management of aLdosterone-producing adrenaL adenomas - does adrenaLectomy increase costs? // Surgery. 2010. VoL. 148. P. 1178-1185; discussion P. 1185.
46. Мельниченко Г.А., Платонова Н.М., Бельцевич Д.Г., Юкина М.Ю. и др. Первичный гиперальдостеронизм: диагностика и лечение. Новый взгляд на проблему. По материалам Проекта клинических рекомендаций Российской ассоциации эндокринологов по диагностике и лечению первичного гиперальдостеронизма // ConsiLium Medicum. 2017. Т. 19, № 4. С. 75-85.
47. Brown J.J., Davies D.L., Ferriss J.B., Fraser R. et aL. Comparison of surgery and proLonged spironoLactone therapy in patients with hypertension, aLdosterone excess, and Low pLasma renin // Br. Med. J. 1972. VoL. 2. P. 729-734.
48. Crane M.G., Harris J.J. Effect of spironoLactone in hypertensive patients // Am. J. Med. Sci. 1970. VoL. 260. P. 311-330.
49. GanguLy A., Luetscher J.A. SpironoLactone therapy in primary aLdosteronism: diagnostic and therapeutic impLications // Systemic Effects of Antihypertensive Agents / ed. M.P. Sambhi. New York : Stratton, 1976. P. 383-392.
50. HeLber A., Wambach G., Hummerich W., Bonner G. et aL. Evidence for a subgroup of essentiaL hypertensives with non-suppressibLe excretion of aLdosterone during sodium Loading // KLin. Wochenschr. 1980. VoL. 58. P. 439-447.
51. Kater C.E., BigLieri E.G., SchambeLan M., Arteaga E. Studies of impaired aLdosterone response to spironoLactone-induced renin and potassium eLevations in adenomatous but not hyperpLastic primary aLdosteronism // Hypertension. 1983. VoL. 5. P. V115-V121.
52. Kremer D., Beevers D.G., Brown J.J., Davies D.L. et aL. SpironoLactone and amiLoride in the treatment of Low renin hyperaLdosteronism and reLated syndromes // CLin. Sci. MoL. Med. SuppL. 1973. VoL. 45, suppL. 1. P. 213s-218s.
53. Wambach G., HeLber A., Bonner G., Hummerich W. et aL. [SpironoLactone in essentiaL hypertension associated with abnormaL aLdosterone reguLation and in Conn's syndrome (author's transL)] // Dtsch. Med. Wochenschr. 1980. VoL. 105. P. 647-651.
54. Lim P.O., Jung R.T., MacDonaLd T.M. Raised aLdosterone to renin ratio predicts antihypertensive efficacy of spironoLactone: a prospective cohort foLLow-up study // Br. J. CLin. PharmacoL. 1999. VoL. 48. P. 756-760.
55. Burgess E.D., Lacourciere Y., RuiLope-Urioste L.M. et aL. Long-term safety and efficacy of the seLective aLdosterone bLocker epLerenone in patients with essentiaL hypertension // CLin. Ther. 2003. VoL. 25. P. 2388-2404.
56. Weinberger M.H., Roniker B., Krause S.L., Weiss R.J. EpLerenone, a seLective aLdosterone bLocker, in miLd-to-moderate hypertension // Am. J. Hypertens. 2002. VoL. 15. P. 709-716.
57. Pitt B., Remme W., Zannad F., Neaton J. et aL. EpLerenone Post-Acute MyocardiaL Infarction Heart FaiLure Efficacy and SurvivaL Study. EpLerenone, a seLective aLdosterone bLocker, in patients with Left ventricuLar dysfunction after myocardiaL infarction // N. EngL. J. Med. 2003. VoL. 348. P. 1309-1321.
REFERENCES
1. Dedov MeL'nichenko G.A. (eds). EndocrinoLogy: nationaL Leadership. Мoscow: Geotar-Меdia; 2009. (in Russian)
2. Conn J.W. PresidentiaL address. I. Painting background. II. Primary aLdosteronism, a new cLinicaL syndrome. J Lab CLin Med. 1955; 45: 3-17.
3. Conn J.W., Cohen E.L., Rovner D.R., Nesbit R.M. NormokaLemic primary aLdosteronism. A detectabLe cause of curabLe "essentiaL" hypertension. JAMA. 1965; 193: 200-6.
4. Conn J.W. The evoLution of primary aLdosteronism 1954-1967. Harvey Lect. 1966-1967; 62: 257-91.
5. KapLan N.M. HypokaLemia in the hypertensive patient, with observations on the incidence of primary aLdosteronism. Ann Intern Med. 1967; 66: 1079-90.
6. Fishman L.M., KucheL O., LiddLe G.W., et aL. Incidence of primary aLdosteronism uncompLicated "essentiaL" hypertension. A prospective study with eLevated aLdosterone secretion and suppressed pLasma renin activity used as diagnostic criteria. JAMA. 1968; 205: 497-502.
7. BergLund G., Andersson O., WiLheLmsen L. PrevaLence of primary and secondary hypertension: studies in a random popuLation sampLe. Br Med J. 1976; 2: 554-6.
8. Tucker R.M., Labarthe D.R. Frequency of surgicaL treatment for hypertension in aduLts at the Mayo CLinic from 1973 through 1975. Mayo CLin Proc. 1977; 52: 549-5.
9. Streeten D.H., Tomycz N., Anderson G.H. ReLiabiLity of screening methods for the diagnosis of primary aLdosteronism. Am J Med. 1979; 67: 403-3.
10. SincLair A.M., IsLes C.G., Brown I., et aL. Secondary hypertension in a bLood pressure cLinic. Arch Intern Med. 1987; 147: 1289-93.
11. Andersen G.S., ToftdahL D.B., Lund J.O., et aL. The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981. J Hum Hypertens. 1988; 2: 187-9.
12. Grim C.E., Weinberger M.H., Higgins J.T., Kramer N.J. Diagnosis of secondary forms of hypertension. A comprehensive protocoL. JAMA. 1977; 237: 1331-5.
13. Gordon R.D., Stowasser M., Tunny T.J., et aL. High incidence of primary aLdosteronism in 199 patients referred with hypertension. CLin Exp PharmacoL PhysioL. 1994; 21: 315-8.
14. FardeLLa C.E., Mosso L., Gomez-Sanchez C., et aL. Primary hyperaLdosteronism in essentiaL hypertensives: prevaLence, biochemicaL profiLe, and moLecuLar bioLogy. J CLin EndocrinoL Metab. 2000; 85: 1863-7.
15. Lim P.O., Dow E., Brennan G., et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens. 2000; 14: 311-5.
16. Loh K.C., Koay E.S., Khaw M.C., et al. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab. 2000; 85: 2854-9.
17. Mulatero P., Stowasser M., Loh K.C., et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004; 89: 1045-50.
18. Mosso L., Carvajal C., Gonzalez A., et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003; 42: 161-5.
19. Schwartz G.L., Turner S.T. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005; 51: 386-94.
20. Hannemann A., Bidlingmaier M., Friedrich N., et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol. 2012; 167: 7-15.
21. Milliez P., Girerd X., Plouin P.F., Blacher J., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45: 1243-8.
22. Stowasser M., Sharman J., Leano R., Gordon R.D., et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005; 90: 5070-6.
23. Funder J.F., Carey R.M., Mantero F., Murad M.H., et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101 (5): 1889-916.
24. Stowasser M., Gordon R.D., Gunasekera T.G., Cowley D.C., et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after "non-selective" screening of hypertensive patients. J Hypertens. 2003; 21: 2149-57.
25. Wu V.C., Kuo C.C., Wang S.M., Liu K.L., et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens. 2011; 29: 1778-86.
26. Hiramatsu K., Yamada T., Yukimura Y., Komiya I., et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981; 141: 1589-93.
27. Stowasser M., Ahmed A.H., Pimenta E., Taylor P.J., et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res. 2012; 44: 170-6.
28. Young W.F., Stanson A.W., Thompson G.B., Grant C.S., et al. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004; 136: 1227-35.
29. Nwariaku F.E., Miller B.S., Auchus R., Holt S., et al. Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg. 2006; 141: 497-502; discussion: 493-502.
30. Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol. 2007; 66: 607-18.
31. Young W.F. Jr. Conventional imaging in adrenocortical carcinoma: update and perspectives. Horm Cancer. 2011; 2: 341-7.
32. Dluhy R.G., Anderson B., Harlin B., Ingelfinger J., et al. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr. 2001; 138: 715-20.
33. So A., Duffy D.L., Gordon R.D., Jeske Y.W., et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens. 2005; 23: 1477-84.
34. Geller D.S., Zhang J., Wisgerhof M.V., Shackleton C., et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008; 93: 3117-23.
35. Young W.F., Stanson A.W., Thompson G.B., Grant C.S., et al. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004; 136: 1227-35.
36. Wolley M.J., Gordon R.D., Ahmed A.H., Stowasser M. Does contra-lateral suppression at adrenal venous sampling predict outcome following unilateral adrenalectomy for primary aldosteronism? A retrospective study. J Clin Endocrinol Metab. 2015; 100: 1477-84.
37. Young W.F., Stanson A.W. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol. 2009; 70: 14-7.
38. Gordon R.D. Primary aldosteronism. J Endocrinol Invest. 1995; 18: 495-511.
39. Ganguly A., Dowdy A.J., Luetscher J.A., Melada G.A. Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab. 1973; 36: 401-4.
40. Gordon R.D., Gomez-Sanchez C.E., Hamlet S.M., Tunny T.J., et al. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essential hypertension. J Hypertens Suppl. 1987; 5: S103-6.
41. Bystrom C.E., Salameh W., Reitz R., Clarke N.J. Plasma renin activity by LC-MS/MS: development of a prototypical clinical assay reveals a subpopulation of human plasma samples with substantial peptidase activity. Clin Chem. 2010; 56: 1561-9.
42. Espiner E.A., Ross D.G., Yandle T.G., Richards A.M., et al. Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. J Clin Endocrinol Metab. 2003; 88: 3637-44.
43. Phillips J.L., Walther M.M., Pezzullo J.C., Rayford W., et al. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab. 2000; 85: 4526-33.
44. Sywak M., Pasieka J.L. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg. 2002; 89: 1587-93.
45. Reimel B., Zanocco K., Russo M.J., Zarnegar R., et al. The management of aldosterone-producing adrenal adenomas - does adrenalectomy increase costs? Surgery. 2010; 148: 1178-85; discussion: 1185.
46. Mel'nichenko G.A., Platonova N.M., Bel'tsevich D.G., Yukina M.Yu., et al. Primary hyperaldosteronism: diagnosis and treatment. A new look at the problem. According to the materials of the Russian Association of Endocrinologists clinical guidelines for primary hyperaldosteronism diagnosis and treatment. Consilium Medicum. 2017; 19 (4): 75-85. (in Russian)
47. Brown J.J., Davies D.L., Ferriss J.B., Fraser R. et al. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br Med J. 1972; 2: 729-34.
48. Crane M.G., Harris J.J. Effect of spironolactone in hypertensive patients. Am J Med Sci. 1970; 260: 311-30.
49. Ganguly A., Luetscher J.A. Spironolactone therapy in primary aldosteronism: diagnostic and therapeutic implications. Systemic Effects of Antihypertensive Agents; ed. M.P. Sambhi. New York: Stratton, 1976: 383-92.
50. Helber A., Wambach G., Hummerich W., Bonner G., et al. Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading. Klin Wochenschr. 1980; 58: 439-47.
51. Kater C.E., Biglieri E.G., Schambelan M., Arteaga E. Studies of impaired aldosterone response to spironolactone-induced renin and potassium elevations in adenomatous but not hyperplastic primary aldosteronism. Hypertension. 1983; 5: V115-21.
52. Kremer D., Beevers D.G., Brown J.J., Davies D.L., et al. Spironolactone and amiloride in the treatment of low renin hyperaldosteronism and related syndromes. Clin Sci Mol Med Suppl. 1973; 45 (suppl 1): 213s-8s.
53. Wambach G., Helber A., Bonner G., Hummerich W., et al. [Spironolactone in essential hypertension associated with abnormal aldosterone regulation and in Conn's syndrome (author's transl)]. Dtsch Med Wochenschr. 1980; 105: 647-51.
54. Lim P.O., Jung R.T., MacDonald T.M. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol. 1999; 48: 756-60.
55. Burgess E.D., Lacourciere Y., Ruilope-Urioste L.M., et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther. 2003; 25: 2388-404.
56. Weinberger M.H., Roniker B., Krause S.L., Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002; 15: 709-16.
57. Pitt B., Remme W., Zannad F., Neaton J., et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21.